As MYC targets are enriched during relapse, our findings suggest that MYC, together with proteins involved in rRNA processing and ribosome biogenesis, are prognostic biomarkers for relapse and potential therapeutic targets in AML. The gene discussed is MYC; the disease is acute myeloid leukemia.